Industry Verticals »

All Categories

Insights »

About TMR »

Hematological Malignancies Market

Hematological Malignancies Market (Disease Condition - Leukemia, Lymphoma, and Myeloma; Therapy - Chemotherapy, Immunotherapy, and Targeted Therapy; Distribution Channel - Hospital Pharmacies, Medical Stores, and E-commerce Platform) - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2016 - 2024

Global Hematological Malignancies Market: Snapshot

Hematological malignancies, commonly known as hematological cancer, is registering a widespread prevalence across the world. According to the National Cancer Institute, hematological cancer is the fifth most commonly occurring cancer, globally, and is the second prominent reason behind the cancer death in the U.S. Researchers expect the incidence of hematological malignancies to increase further in the coming years, which will result in the growing need for its treatment, impacting the global hematological malignancies market greatly.

The opportunity in the worldwide market for hematological malignancies, which stood at US$27.4 bn in 2015, is likely to expand at a CAGR of 7.50% during the period from 2016 to 2024 and reach a value of US$51.9 bn by 2024.

The rich product pipeline and the improvement in the reimbursement scenario are likely to drive the growth of the market for hematological malignancies treatment, worldwide, in the near future. Moreover, the rising trend of patent protection is also expected to boost this market considerably in the coming years.

hematological malignancies market

 

Demand for Immunotherapy to Remain Strong

Immunotherapy, chemotherapy, and targeted therapy are the three most common treatment methods for hematological malignancies. Among these, immunotherapy led the demand in 2015 with a share of 41.3% in the overall market. The efficiency of immunotherapy, coupled with a lower risk of side effects, has influenced its demand considerably over the last few years.

Going forward, blockbuster drugs, such as Pomalyst, Rituxan, and Revlimid, are impacting the demand for immunotherapy positively and are expected to continue doing do throughout the forecast period, leading to a substantial rise in the immunotherapy segment. Targeted therapy is also anticipated to exhibit promising growth in the near future on account of the massive investments made for the development of targeted therapy products.

Presence of Advanced Healthcare Infrastructure to Ensure Dominance of North America

The worldwide market for hematological malignancies stretches across Asia Pacific, North America, Europe, the Middle East and Africa, and Latin America. Supported by the presence of an advanced medical and healthcare infrastructure, North America market for hematological malignancies has been leading the overall market. The growing prevalence of hematological cancer, the rising awareness level of people, and the availability of modern diagnostic technologies are expected to reflect positively on the demand for hematological malignancies therapeutics in the coming years, ensuring the dominance of this regional market.

Apart from this, Asia Pacific is also projected to experience steady growth in the demand for hematological malignancies therapeutics over the next few years. The increasing incidence of blood cancer-related mutation diagnostic cases, rising count of government-supported healthcare programs, and the imminent launch of novel drugs is expected to boost the Asia Pacific market for hematological malignancies during the forecast period. Latin America and the Middle East and Africa are anticipated to offer lucrative growth prospects to market players in the years to come due to the availability of untapped opportunities in abundance.

AbbVie Inc., Bristol-Myers Squibb Co., Celgene Corp., F. Hoffmann-La Roche Ltd., GlaxoSmithKline Plc., Johnson & Johnson, Novartis AG, Pfizer Inc., and Teva Pharmaceutical Industries Ltd. are some of the leading players in the global market for hematological malignancies.

Expanding Investments and Rising Cancer Cases to Bring Immense Growth Prospects for the Hematological Malignancies Market

The growing prevalence of cancer across the world has led to a large number of fatalities. The expanding prevalence of cancer-related cases is leading to the innovation and development of new drugs and treatment types. Diverse types of drugs and treatment options are available for various cancer types. Hematological cancer or hematological malignancy is one of the most prominent cancer types that need to be tackled effectively. Thus, all these factors will increase the growth rate of the hematological malignancies market between 2016 and 2024.

  • Hematological malignancies start in the cells of blood-developing tissues, such as the bone marrow or the cells of the immune system. They also affect the lymph nodes. The alarming rate of the increase in hematological cancer cases will serve as a prominent growth indicator for the hematological malignancies market. Furthermore, the growing number of fatalities due to hematological malignancies is also urging many pharmaceutical companies to produce effective drugs and treatment options.
  • Research and development activities play a vital role in the growth of the hematological malignancies market. The players in the hematological malignancies market invest extensively in these activities to discover new formulations and affordable drugs. These aspects help in increasing the revenue of the players, eventually multiplying the growth rate.
  • The investments of various firms and conglomerates in the hematological malignancies market will serve as a boon and will lead to extensive growth prospects. The mergers and acquisitions will further add extra stars of growth to the hematological malignancies market. The acquisitions and mergers help in cementing the foothold of the players in the hematological malignancies market.
  • The COVID-19 pandemic has a minimal negative impact on the growth of the hematological malignancies market. The healthcare sector was exempted from the strict lockdown restrictions which did not lead to any prominent damage to the hematological malignancies market.

    1. Preface
         1.1. Research Scope
         1.2. Market Segmentation
         1.3. Research Objectives
         1.4. Key Questions Answered

    2. Assumptions and Research Methodology
         2.1. Report Assumptions
         2.2. Acronyms Used
         2.3. Research Methodology

    3. Executive Summary
         3.1. Global Hematological malignancies Market Snapshot
         3.2. Market Opportunity Map

    4. Market Overview
         4.1. Product Overview
         4.2. Key Industry Events
         4.3. Death Rate of Leukemia, by Country
         4.4. Death Rate of Cancer, by Country

    5. Market Dynamics
         5.1. Drivers and Restraints Snapshot Analysis
         5.2. Drivers
         5.3. Restraints
         5.4. Opportunities
         5.5. Opportunity Analysis
         5.6. Porter’s Analysis
         5.7. Pipeline Analysis (Phase III) till 2024

    6. Global Hematological Malignancies Market Analysis, by Disease Condition
         6.1. Key Findings
         6.2. Introduction
         6.3. Leukemia
         6.4. Lymphoma
         6.5. Myeloma
         6.6. Key Trends
         6.7. Market Attractiveness Analysis

    7. Global Hematological Malignancies Market Analysis, by Therapy
         7.1. Key Findings
         7.2. Introduction
         7.3. Chemotherapy
         7.4. Immunotherapy
         7.5. Targeted Therapy
         7.6. Key Trends
         7.7. Market Attractiveness Analysis

    8. Global Hematological Malignancies Market Analysis, by Distribution Channel
         8.1. Key Findings
         8.2. Introduction
         8.3. Hospital Pharmacies
         8.4. Medical Stores
         8.5. E-commerce Platform
         8.6. Key Trend Analysis
         8.7. Market Attractiveness Analysis

    9. Global Hematological Malignancies Market Analysis, by Region
         9.1. North America
         9.2. Europe
         9.3. Asia Pacific
         9.4. Latin America
         9.5. Middle East & Africa
         9.6. Market Attractiveness Analysis

    10. North America Hematological malignancies Market Analysis
         10.1. North America Hematological Malignancies Market Size Forecast, By Country, 2016-2024
         10.2. North America Hematological Malignancies Market Size Forecast, By Disease Condition, 2016-2024
         10.3. North America Hematological Malignancies Market Size Forecast, By Therapy, 2016-2024
         10.4. North America Hematological Malignancies Market Size Forecast, By Distribution Channel, 2016-2024
         10.5. North America Hematological Malignancies Market Attractiveness Analysis, 2016-2024

    11. Europe Hematological Malignancies Market Analysis
         11.1. Europe Hematological Malignancies Market Size Forecast, By Country, 2016-2024
         11.2. Europe Hematological Malignancies Market Size Forecast, By Disease Condition, 2016-2024
         11.3. Europe Hematological Malignancies Market Size Forecast, By Therapy, 2016-2024
         11.4. Europe Hematological Malignancies Market Size Forecast, By Distribution Channel, 2016-2024
         11.5. Europe Hematological Malignancies Market Attractiveness Analysis, 2016-2024

    12. Asia Pacific Hematological Malignancies Market Analysis
         12.1. Asia Pacific Hematological Malignancies Market Size Forecast, By Country, 2016-2024
         12.2. Asia Pacific Hematological Malignancies Market Size Forecast, By Disease Condition, 2016-2024
         12.3. Asia Pacific Hematological Malignancies Market Size Forecast, By Therapy, 2016-2024
         12.4. Asia Pacific Hematological Malignancies Market Size Forecast, By Distribution Channel, 2016-2024
         12.5. Asia Pacific Hematological Malignancies Market Attractiveness Analysis, 2016-2024

    13. Latin America Hematological Malignancies Market Analysis
         13.1. Latin America Hematological Malignancies Market Size Forecast, By Country, 2016-2024
         13.2. Latin America Hematological Malignancies Market Size Forecast, By Disease Condition, 2016-2024
         13.3. Latin America Hematological Malignancies Market Size Forecast, By Therapy, 2016-2024
         13.4. Latin America Hematological Malignancies Market Size Forecast, By Distribution Channel, 2016-2024
         13.5. Latin America Hematological Malignancies Market Attractiveness Analysis, 2016-2024

    14. Middle East & Africa Hematological Malignancies Market Analysis
         14.1. Middle East & Africa Hematological Malignancies Market Size Forecast, By Country, 2016-2024
         14.2. Middle East & Africa Hematological Malignancies Market Size Forecast, By Disease Condition, 2016-2024
         14.3. Middle East & Africa Hematological Malignancies Market Size Forecast, By Therapy, 2016-2024
         14.4. Middle East & Africa Hematological Malignancies Market Size Forecast, By Distribution Channel, 2016-2024
         14.5. Middle East & Africa Hematological Malignancies Market Attractiveness Analysis, 2016-2024

    15. Competitive Landscape
         15.1. Hematological Malignancies Market Share Analysis By Company (2015)
         15.2. Competition Matrix
                 15.2.1. Teva Pharmaceutical Industries Ltd.
                 15.2.2. GlaxoSmithKline plc
                 15.2.3. Johnson & Johnson
                 15.2.4. Bristol Myers Squibb
                 15.2.5. F. Hoffmann-La Roche Ltd. 
                 15.2.6. Merck & Co., Inc. 
                 15.2.7. Novartis AG 
                 15.2.8. Pfizer, Inc. 

    16. Company Profiles
         16.1. AbbVie, Inc.
                 16.1.1. Company Details
                 16.1.2. Company Description
                 16.1.3. Business Overview
                 16.1.4. SWOT Analysis
                 16.1.5. Financial Analysis
                 16.1.6. Strategic Overview
         16.2. Bristol-Myers Squibb Company
                 16.2.1. Company Details
                 16.2.2. Company Description
                 16.2.3. Business Overview
                 16.2.4. SWOT Analysis
                 16.2.5. Financial Analysis
                 16.2.6. Strategic Overview
         16.3. Celgene Corporation
                 16.3.1. Company Details
                 16.3.2. Company Description
                 16.3.3. Business Overview
                 16.3.4. SWOT Analysis
                 16.3.5. Financial Analysis
                 16.3.6. Strategic Overview
         16.4. F. Hoffmann-La Roche Ltd.
                 16.4.1. Company Details
                 16.4.2. Company Description
                 16.4.3. Business Overview
                 16.4.4. SWOT Analysis
                 16.4.5. Financial Analysis
                 16.4.6. Strategic Overview
         16.5. GlaxoSmithKline plc
                 16.5.1. Company Details
                 16.5.2. Company Description
                 16.5.3. Business Overview
                 16.5.4. SWOT Analysis
                 16.5.5. Financial Analysis
                 16.5.6. Strategic Overview
         16.6. Johnson & Johnson
                 16.6.1. Company Details
                 16.6.2. Company Description
                 16.6.3. Business Overview
                 16.6.4. SWOT Analysis
                 16.6.5. Financial Analysis
                 16.6.6. Strategic Overview
         16.7. Novartis AG
                 16.7.1. Company Details
                 16.7.2. Company Description
                 16.7.3. Business Overview
                 16.7.4. SWOT Analysis
                 16.7.5. Financial Analysis
                 16.7.6. Strategic Overview
         16.8. Pfizer, Inc.
                 16.8.1. Company Details
                 16.8.2. Company Description
                 16.8.3. Business Overview
                 16.8.4. SWOT Analysis
                 16.8.5. Financial Analysis
                 16.8.6. Strategic Overview
         16.9. Teva Pharmaceutical Industries Ltd.
                 16.9.1. Company Details
                 16.9.2. Company Description
                 16.9.3. Business Overview
                 16.9.4. SWOT Analysis
                 16.9.5. Financial Analysis
                 16.9.6. Strategic Overview

    List of Tables

    TABLE 1 Global Hematological Malignancies Market Size (US$ Mn) Forecast, by Pipeline Molecule, till 2024
    TABLE 2 Global Hematological Malignancies Market Size (US$ Mn) Forecast, by Disease Condition, 2016–2024
    TABLE 3 Global Hematological Malignancies Market Size (US$ Mn) Forecast, by Therapy, 2016–2024
    TABLE 4 Global Hematological Malignancies Market Size (US$ Mn) Forecast, by Distribution Channel, 2016–2024
    TABLE 5 Global Hematological Malignancies Market Size (US$ Mn) Forecast, by Region, 2016–2024
    TABLE 6 North America Hematological Malignancies Market Size (US$ Mn) Forecast, by Country, 2016–2024
    TABLE 7 North America Hematological Malignancies Market Size (US$ Mn) Forecast, by Disease Condition, 2016–2024
    TABLE 8 North America Hematological Malignancies Market Size (US$) Forecast, by Therapy, 2016–2024
    TABLE 9 North America Hematological Malignancies Market Size (US$ Mn) Forecast, by Distribution Channel, 2016–2024
    TABLE 10 Europe Hematological Malignancies Market Size (US$ Mn) Forecast, by Country, 2016–2024
    TABLE 11 Europe Hematological Malignancies Market Size (US$ Mn) Forecast, by Disease Condition, 2016–2024
    TABLE 12 Europe Hematological Malignancies Market Size (US$) Forecast, by Therapy, 2016–2024
    TABLE 13 Europe Hematological Malignancies Market Size (US$ Mn) Forecast, by Distribution Channel, 2016–2024
    TABLE 14 Asia Pacific Hematological Malignancies Market Size (US$ Mn) Forecast, by Country, 2016–2024
    TABLE 15 Asia Pacific Hematological Malignancies Market Size (US$ Mn) Forecast, by Disease Condition, 2016–2024
    TABLE 16 Asia Pacific Hematological Malignancies Market Size (US$) Forecast, by Therapy, 2016–2024
    TABLE 17 Asia Pacific Hematological Malignancies Market Size (US$ Mn) Forecast, by Distribution Channel, 2016–2024
    TABLE 18 Latin America Hematological Malignancies Market Size (US$ Mn) Forecast, by Country, 2016–2024
    TABLE 19 Latin America Hematological Malignancies Market Size (US$ Mn) Forecast, by Disease Condition, 2016–2024
    TABLE 20 Latin America Hematological Malignancies Market Size (US$) Forecast, by Therapy, 2016–2024
    TABLE 21 Latin America Hematological Malignancies Market Size (US$ Mn) Forecast, by Distribution Channel, 2016–2024
    TABLE 22 MEA Hematological Malignancies Market Size (US$ Mn) Forecast, by Country, 2016–2024
    TABLE 23 MEA Hematological Malignancies Market Size (US$ Mn) Forecast, by Disease Condition, 2016–2024
    TABLE 24 MEA Hematological Malignancies Market Size (US$) Forecast, by Therapy, 2016–2024

    List of Figures

    FIG. 1 Global Hematological Malignancies Market Value Share Analysis, by Disease Condition, 2015 and 2024
    FIG. 2 Global Leukemia Market Revenue (US$ Mn), 2014–2024
    FIG. 3 Global Lymphoma Market Revenue (US$ Mn), 2014–2024
    FIG. 4 Global Myeloma Market, Revenue (US$ Mn), 2014–2024
    FIG. 5 Hematological Malignancies Market Attractiveness Analysis, by Disease Condition, 2015
    FIG. 6 Global Hematological Malignancies Market Value Share Analysis, by Therapy, 2015 and 2024
    FIG. 7 Global Chemotherapy Market Revenue (US$ Mn), 2014–2024
    FIG. 8 Global Immunotherapy Market Revenue (US$ Mn), 2014–2024
    FIG. 9 Global Targeted Therapy Market, Revenue (US$ Mn), 2014–2024
    FIG. 10 Hematological Malignancies Market Attractiveness Analysis, by Therapy, 2015
    FIG. 11 Global Hematological Malignancies Market Value Share Analysis, by Distribution Channel, 2015 and 2024
    FIG. 12 Global Hospital Pharmacies Market Revenue (US$ Mn), 2014–2024
    FIG. 13 Global Medical Stores Market Revenue (US$ Mn), 2014–2024
    FIG. 14 Global E-commerce Market, Revenue (US$ Mn), 2014–2024
    FIG. 15 Hematological Malignancies Market Attractiveness Analysis, by Distribution Channel, 2015
    FIG. 16 North America Hematological Malignancies Market Size (US$ Mn) Forecast, 2016–2024
    FIG. 17 Europe Hematological Malignancies Market Size (US$ Mn) Forecast, 2016–2024
    FIG. 18 APAC Hematological Malignancies Market Size (US$ Mn) Forecast, 2016–2024
    FIG. 19 Latin America Hematological Malignancies Market Size (US$ Mn) Forecast, 2016–2024
    FIG. 20 MEA Hematological Malignancies Market Size (US$ Mn) Forecast, 2016–2024
    FIG. 21 Global Hematological Malignancies Market Attractiveness Analysis, by Region
    FIG. 22 U.S. Hematological Malignancies Market Size (US$ Mn) Forecast, 2016–2024
    FIG. 23 Canada Hematological Malignancies Market Size (US$ Mn) Forecast, 2016–2024
    FIG. 24 North America Hematological Malignancies Market Attractiveness Analysis, by Country
    FIG. 25 North America Hematological Malignancies Market Attractiveness Analysis, by Disease Condition
    FIG. 26 North America Hematological Malignancies Market Attractiveness Analysis, by Therapy
    FIG. 27 North America Hematological Malignancies Market Attractiveness Analysis, by Distribution Channel
    FIG. 28 Germany Hematological Malignancies Market Size (US$ Mn) Forecast, 2016–2024
    FIG. 29 France Hematological Malignancies Market Size (US$ Mn) Forecast, 2016–2024
    FIG. 30 The U.K. Hematological Malignancies Market Size (US$ Mn) Forecast, 2016–2024
    FIG. 31 Italy Hematological Malignancies Market Size (US$ Mn) Forecast, 2016–2024
    FIG. 32 Spain Hematological Malignancies Market Size (US$ Mn) Forecast, 2016–2024
    FIG. 33 Rest of Europe Hematological Malignancies Market Size (US$ Mn) Forecast, 2016–2024
    FIG. 34 Europe Hematological Malignancies Market Attractiveness Analysis, by Country
    FIG. 35 Europe Hematological Malignancies Market Attractiveness Analysis, by Disease Condition
    FIG. 36 Europe Hematological Malignancies Market Attractiveness Analysis, by Therapy
    FIG. 37 Europe Hematological Malignancies Market Attractiveness Analysis, by Distribution Channel
    FIG. 38 Japan Hematological Malignancies Market Size (US$ Mn) Forecast, 2016–2024
    FIG. 39 China Hematological Malignancies Market Size (US$ Mn) Forecast, 2016–2024
    FIG. 40 India Hematological Malignancies Market Size (US$ Mn) Forecast, 2016–2024
    FIG. 41 Rest of APAC Hematological Malignancies Market Size (US$ Mn) Forecast, 2016–2024
    FIG. 42 Asia Pacific Hematological Malignancies Market Attractiveness Analysis, by Country
    FIG. 43 Asia Pacific Hematological Malignancies Market Attractiveness Analysis, by Disease Condit
    FIG. 44 Asia Pacific Hematological Malignancies Market Attractiveness Analysis, by Therapy
    FIG. 45 Asia Pacific Hematological Malignancies Market Attractiveness Analysis, by Distribution Channel
    FIG. 46 Brazil Hematological Malignancies Market Size (US$ Mn) Forecast, 2016–2024
    FIG. 47 Mexico Hematological Malignancies Market Size (US$ Mn) Forecast, 2016–2024
    FIG. 48 Rest of LATAM Hematological Malignancies Market Size (US$ Mn) Forecast, 2016–2024
    FIG. 49 Latin America Hematological Malignancies Market Attractiveness Analysis, by Country
    FIG. 50 Latin America Hematological Malignancies Market Attractiveness Analysis, by Disease Condition
    FIG. 51 Latin America Hematological Malignancies Market Attractiveness Analysis, by Therapy
    FIG. 52 Latin America Hematological Malignancies Market Attractiveness Analysis, by Distribution Channel
    FIG. 53 South Africa Hematological Malignancies Market Size (US$ Mn) Forecast, 2016–2024
    FIG. 54 Saudi Arabia Hematological Malignancies Market Size (US$ Mn) Forecast, 2016–2024
    FIG. 55 Rest of MEA Hematological Malignancies Market Size (US$ Mn) Forecast, 2016–2024
    FIG. 56 MEA Hematological Malignancies Market Attractiveness Analysis, by Country
    FIG. 57 MEA Hematological Malignancies Market Attractiveness Analysis, by Disease Condition
    FIG. 58 MEA Hematological Malignancies Market Attractiveness Analysis, by Therapy
    FIG. 59 MEA Hematological Malignancies Market Attractiveness Analysis, by Distribution Channel
    FIG. 60 Hematological Malignancies Market Share Analysis, by Company (2015)

Copyright © Transparency Market Research, Inc. All Rights reserved

Hematological Malignancies Market

Schedule a Call